OptimumBank Holdings Inc. (NYSE American: OPHC)

The QualityStocks Daily Newsletter would like to spotlight OptimumBank Holdings Inc. (NYSE American: OPHC).

OptimumBank Holdings (NYSE American: OPHC) reported net income of $4.7 million, or $0.39 per basic share, for the first quarter of 2026, compared to $3.9 million in the prior-year period, driven by higher net interest income and modest gains in noninterest income. The company also posted strong balance sheet expansion, with total deposits rising 17.3% to $1.09 billion and gross loans increasing 13.8% to $1.09 billion during the quarter, reflecting continued momentum across its relationship-based banking model.

To view the full press release, visit https://ibn.fm/7DaVl

OptimumBank Holdings Inc. (NYSE American: OPHC) is a single bank holding company that owns 100% of OptimumBank, a community bank headquartered in Fort Lauderdale, Florida. OptimumBank offers relationship-driven banking available in person, by phone, and online, serving both local and international clients by offering an alternative to the high fees and impersonal service of larger institutions. Its expertise in real estate and commercial lending has made it a preferred partner for borrowers seeking knowledgeable, accessible financial support.

Driven by disciplined execution and a commitment to local relationships, OptimumBank has experienced substantial organic growth, positioning itself as one of the fastest-growing community banks in the region. The company has surpassed $1 billion in total assets and remains focused on scaling efficiently, maintaining sound credit quality, and delivering strong returns for shareholders.

Looking ahead, the bank is embracing technology modernization while remaining grounded in the principles of relationship-based banking. A new open-architecture core platform, targeted loan expansion, and sustained deposit growth are key pillars of its forward strategy.

Products

OptimumBank offers a full suite of business and personal banking solutions, including Business Banking, Business Lending, SBA Lending Solutions, Treasury Management, and Personal Banking. Its lending focus includes commercial real estate, multifamily, construction, residential, and consumer loans.

The bank achieved Preferred Lender status with the Small Business Administration in just over two years—an uncommon accomplishment—and rapidly scaled its SBA lending operations from zero in record time. Its treasury services and deposit products are supported by a stable core funding base, with a growing percentage of noninterest-bearing demand deposits.

In late 2025, OptimumBank is rolling out a next-generation core banking platform with API-based architecture, enabling paperless processing, streamlined onboarding, and enhanced treasury management tools.

OptimumBank is deeply engaged in the community, providing support to organizations such as Habitat for Humanity of Broward, along with schools, synagogues, and many other nonprofits that are important to its customers and neighbors.

Market Opportunity

The U.S. community banking sector represents a multi-trillion-dollar opportunity, especially in underserved regions where local institutions continue to consolidate. South Florida’s real estate market and growing population create robust demand for personalized commercial lending, construction loans, and deposit services.

According to Mordor Intelligence, the U.S. commercial banking market is expected to grow from $732.5 billion in 2025 to $915.45 billion by 2030, reflecting a compound annual growth rate (CAGR) of 4.56%. Within this landscape, OptimumBank is well-positioned to benefit from regional consolidation and rising customer dissatisfaction with national banks.

OptimumBank’s continued investments in talent, technology, and compliance infrastructure ensure scalability as it targets its next major milestone: becoming a top 200 publicly traded bank in the United States. The bank has maintained a track record of net recoveries in recent years, with no loan losses in over seven years and no defaults in its current loan portfolio. In addition, OptimumBank has near-zero exposure to long-dated, low-yield bonds, avoiding the balance sheet drag that has pressured many regional peers.

Leadership Team

Moishe Gubin, Chairman of OptimumBank Holdings, has been a director since 2010. He is also the CEO of Strawberry Fields REIT and previously served as CFO of Infinity Healthcare Management. Gubin is a licensed CPA in New York and the founder of the Midwest Torah Center.

Timothy Terry, President and CEO, has led OptimumBank since 2013 and has over 35 years of banking experience. He previously held senior roles at Enterprise Bank of Florida and other financial institutions, with a background in lending, branch administration, and sales.

Elliot Nunez, EVP and CFO, joined the bank in 2020. He previously served as CFO for Brickell Bank and Mellon United National Bank and worked at KPMG. Nunez is a licensed CPA and Chartered Global Management Accountant.

OptimumBank Holdings Inc. (NYSE American: OPHC), closed Friday's trading session at $5.52, up 1.6575%, on 39,975 volume. The average volume for the last 3 months is 37,823 and the stock's 52-week low/high is $3.91/$5.59.

Recent News

• OptimumBank Holdings Inc. (NYSE American: OPHC) - InvestorNewsBreaks - OptimumBank Holdings, Inc. (NYSE American: OPHC) Reports Q1 2026 Net Income of $4.7M Amid Strong Loan and Deposit Growth
• NetworkNewsBreaks - OptimumBank Holdings, Inc. (NYSE American: OPHC) Gains Buy Rating and $8 Price Target as Brean Capital Initiates Coverage
• InvestorNewsBreaks - OptimumBank Holdings, Inc. (NYSE American: OPHC) Gains Coverage From Alliance Global Partners With Buy Rating

Safe Pro Group Inc. (NASDAQ: SPAI)

The QualityStocks Daily Newsletter would like to spotlight Safe Pro Group Inc. (NASDAQ: SPAI).

• Safe Pro Group recently began the commercial rollout of NODE-X, a next-gen miniaturized AI-powered edge compute processor of drone footage for threat detection.
• The rollout began at a U.S. Army Exercise, and NODE-X is scheduled to be a part of additional U.S. Army exercises throughout the second quarter of 2026.
• NODE-X is powered by Safe Pro’s patented Safe Pro Object Threat Detection (“SPOTD”), a powerful technology used to rapidly analyze drone imagery and video to identify and detect small explosive threats.

Safe Pro Group (NASDAQ: SPAI) , a developer of AI-enabled security, defense, and situational awareness solutions, recently started the commercial rollout of NODE-X at a U.S. Army exercise ( https://ibn.fm/5IdSl ).

Safe Pro Group Inc. (NASDAQ: SPAI) is a mission-driven technology company delivering advanced AI-powered security and defense solutions. It is focused on serving customers in the defense, homeland security, humanitarian, law enforcement, and commercial markets where its AI, drone-based services and ballistic protective gear can synergistically deliver safety and operational efficiency.

At the heart of Safe Pro’s mission is its patented artificial intelligence (AI), machine learning (ML), deep learning and applied computer vision software technology. These tools are currently being used to rapidly detect small objects in drone-based video and imagery such as landmines and unexploded ordnance (UXO), enabling safer and more efficient field operations across global conflict and post-conflict zones and supporting efforts to improve the reliability of critical infrastructure. The company’s vision is to lead the evolution of security and threat detection through AI innovation, while its mission is to empower governments, enterprises, and humanitarian organizations with tools to respond to evolving threats at scale.

With a team of leaders and subject matter experts drawn from the defense, technology, and public safety sectors, Safe Pro Group delivers U.S.-developed next-generation AI and drone services through its Safe Pro AI and Airborne Response units and high-performance, American-made ballistic protective solutions through its Safe-Pro USA subsidiary.

The company is headquartered in Aventura, Florida.

Products

Safe Pro Group’s three business units operate across software, hardware, and field services to deliver a comprehensive suite of solutions. Each division plays a distinct role in supporting defense, humanitarian and public safety missions around the world.

Safe Pro AI

Safe Pro AI’s core AI-powered computer vision technology enables the rapid analysis of drone-based imagery to autonomously detect objects of interest. Its flagship product, SpotlightAI™ can detect and label over 150 types of explosive threats including landmines, cluster munitions, and unexploded ordnance (UXO). Built on more than two years of real-world usage in Ukraine and now including additional imagery being gathered from the Asian-Pacific region and Africa, SpotlightAI™ rapidly processes and creates high-resolution maps supported by the hyper scalability of the Amazon Web Services (AWS) cloud or detects threats in real-time locally through its OnSite Windows-based software application. Today, the platform boasts one of the world’s largest datasets built on over 1.6 million real-world battlefield images from Ukraine, identifying 28,000+ threats across more than 6,750 hectares, an area equivalent in size to Manhattan.

Airborne Response

Airborne Response is a leading provider of mission critical drone services using U.S. Government-compliant small uncrewed aircraft systems (sUAS) (drones). It serves enterprises in utilities & telecom and insurance with a full-range of drone-based critical infrastructure inspection and monitoring solutions as well as Drone-as-a-First Responder (DFR) services for law enforcement and public safety. It provides customers with actionable intelligence though data capture, analytics and processing powered by AI.

Safe-Pro USA

Safe-Pro USA manufactures ultra-premium, American-made ballistic protection systems including advanced body armor and ballistic plates as well as complete Explosive Ordnance Disposal (EOD) suits, demining aprons, and bomb blankets. All products exceed U.S. and NATO standards and are designed, engineered, and produced in the U.S., supporting customers across military, humanitarian, and law enforcement sectors.

Market Opportunity

Harnessing its patented, real-time, AI-powered processing of drone-based imagery, Safe Pro is creating a uniquely powerful ‘Next-Gen’ approach to situational awareness supporting ground-based personnel in safely completing their defense/military, humanitarian, law enforcement & commercial missions.

The global threat posed by landmines and UXO spans nearly 60 countries, affecting millions of civilians and imposing significant economic burdens, particularly in agriculture and infrastructure. In Ukraine alone, the contamination of 17 million hectares has resulted in $50+ billion in agricultural losses, with World Bank estimates projecting $30 billion needed in demining costs. According to the Landmine Monitor 2024, regions in Asia, Africa, and Latin America continue to report high casualty rates.

Safe Pro is positioned to capture a portion of the $15 billion+ global defense tech market, especially in AI-driven battlefield intelligence, drone surveillance, and threat detection. As a U.S.-based AI and defense technology provider with a HUBZone-certified manufacturing arm, Safe Pro is eligible for federal and state procurement programs, public safety grants, and critical infrastructure contracts, as well as global humanitarian demining efforts.

Leadership Team

Dan Erdberg, Chairman and CEO, brings over 20 years of experience as a C-level technology executive. He has led multiple Nasdaq listings in the drone, 5G, and satellite communications sectors, raised over $50 million in growth capital, and spearheaded Safe Pro Group’s corporate strategy and acquisitions.

Theresa Carlise, Chief Financial Officer, has more than 30 years of experience in financial leadership roles for public companies. Her expertise includes equity transactions, strategic planning, and financial restructuring. She served as Chief Financial Officer, Secretary, Treasurer and Director of various publicly traded companies within the retail, telecommunications, distribution, transportation, mortgage banking and construction sectors.

Pravin Borkar, CTO and Director (President, Safe-Pro USA), has over 30 years of experience in the engineering and manufacturing of ballistic protection systems for the U.S. Department of Defense. He has developed armor solutions for personnel and aircraft platforms including the CH-53 and Blackhawk.

Christopher Todd, President (Airborne Response), is a drone industry veteran and Certified Emergency Manager (CEM®) with more than 30 years of experience. He founded Airborne Response and is President of AUVSI Florida, with expertise in public safety drone deployment and emergency response.

Safe Pro Group Inc. (NASDAQ: SPAI), closed Friday's trading session at $4.36, up 0.2298851%, on 83,507 volume. The average volume for the last 3 months is 201,577 and the stock's 52-week low/high is $2.39/$9.1599.

Recent News

• Safe Pro Group Inc. (NASDAQ: SPAI) - Safe Pro Group Inc. (NASDAQ: SPAI) Reveals Its Next-Gen Miniature AI-Powered Edge Compute Processor of Drone Footage for Threat Detection
• Safe Pro Reports on Share Repurchase Program, Reinforcing Commitment to Shareholder Value and Capital Return
• DefenseNewsBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Repurchases 400,000 Shares Under $3 Million Buyback Program

Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF)

The QualityStocks Daily Newsletter would like to spotlight Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF).

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Integrated geochemical and geophysical data point to structurally controlled mineralization at Atikokan rare earth property.
• Dashwa Gneiss Complex emerges as the primary focus for follow-up work.
• Soil, rock, and sediment sampling indicate consistent rare earth element (“REE”) anomalies.
• Results support a coherent exploration model rather than isolated occurrences.
• The project aligns with rising strategic demand for domestic REE supply in North America.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF) , a Canadian mineral exploration company focused on rare earth projects across North America, has refined its exploration strategy at the Atikokan Rare Earth Property in northwestern Ontario, identifying priority target zones following a comprehensive integration of geochemical assays and geophysical data. The findings mark a shift from early-stage sampling toward more targeted exploration planning ( https://ibn.fm/hbas0 ).

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF) , a Canadian mineral exploration company focused on rare earth projects across North America, is positioning itself as the rare earth elements (“REE”) market has moved from a niche segment of the mining industry to a strategic focal point for governments and investors. “Powermax’s approach reflects a portfolio model rather than a single-asset bet,” reads a recent article. “The company holds interests in several REE exploration projects across North America, including the Atikokan project in Ontario, the Cameron project in British Columbia, and the Ogden Bear Lodge project in Wyoming. It has also outlined exploration plans for the Pinard project in northern Ontario. This geographic spread offers exposure to multiple geological settings and regulatory regimes, while also aligning with jurisdictions considered supportive of mining development.”

To view the full article, visit https://ibn.fm/1FSLJ

Disseminated on behalf of Powermax Minerals Inc., may include paid advertisements.

Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) is a Canadian mineral exploration company developing a portfolio of rare earth element (“REE”) projects across Tier-1 jurisdictions in Canada and the United States. Focused on discovery, responsible advancement, and alignment with North America’s critical-minerals strategy, the company targets areas with geological potential for REE-bearing pegmatites and granitic systems.

Its exploration model emphasizes modern geophysics, data integration, and systematic de-risking through technical work. By concentrating on projects with clear infrastructure advantages and policy support, Powermax seeks to contribute meaningfully to regional supply-chain independence in critical minerals vital to electrification and advanced manufacturing.

The company’s growing asset base includes four core REE projects, Atikokan, Cameron, Pinard and Ogden Bear Lodge, positioned within highly prospective geological corridors.

Powermax Minerals is headquartered in Toronto, Ontario.

Projects

Atikokan REE Project – Northwestern Ontario

Powermax’s flagship Atikokan Rare Earth Element Project covers 9,416 hectares across three mineral claim blocks (A, B, and C) approximately 35 kilometers northwest of the town of Atikokan in the Thunder Bay Mining District. Located along the White Otter–Dashwa corridor, the project hosts REE-enriched granitic and pegmatitic systems supported by strong radiometric and geochemical signatures.

In 2025, Powermax completed airborne magnetic and gamma-ray spectrometric surveys, geological mapping, and geochemical sampling. An integrated interpretation released in November 2025 outlined a structural–geochemical corridor of REE enrichment, with Total Rare Earth Element (TREE) values from 254 ppm to 1,947 ppm across Blocks B and C. The company is currently advancing surface validation and target ranking for follow-up work.

Cameron REE Project – British Columbia

The Cameron Project, which the company holds an option to acquire, is located about 30 kilometers south of Revelstoke in the Kamloops Mining Division and comprises three contiguous mineral claims totaling 2,984 hectares.

Hosted within the Monashee Group, the property contains NYF-type granitic pegmatites and gneissic units known to carry both light and heavy REEs. Phase 1 exploration, completed under NI 43-101 recommendations, produced TREE values ranging from 17 ppm to 1,943 ppm, with heavy mineral concentrate samples up to 7,561 ppm. These findings confirmed consistent REE enrichment and led to the launch of Phase 2 exploration in October 2025 to expand mapping and refine drill targets.

Ogden Bear Lodge REE Project – Wyoming, USA

Powermax owns a 100% interest in the Ogden Bear Lodge Project, covering 22 lode claims (184 hectares) in Crook County, Wyoming. The property is prospective for high-grade neodymium-praseodymium (Nd/Pr) oxide mineralization and shares a border with Rare Element Resources’ Bear Lodge Critical Rare Earth Project. That neighboring project has received $24.2 million in U.S. Department of Energy support and a non-binding EXIM Bank letter of interest for up to $553 million in debt financing, highlighting the strategic value of this emerging U.S. REE district.

Pinard Rare Earths Project – Northern Ontario

In November 2025, Powermax Minerals announced plans to acquire a 100% interest in the Pinard Rare Earths Project, located roughly 70 kilometers north-northeast of Kapuskasing, Ontario. The property consists of 255 contiguous claims totaling 5,178 hectares within the Pinard Intrusive Rock Complex, an alkaline igneous system characterized by nepheline syenites and peralkaline granites commonly associated with REE-bearing mineralization.

Market Opportunity

Global demand for rare earth elements is projected to triple—from 59,000 tonnes in 2022 to 176,000 tonnes by 2035—driven by rapid electric-vehicle adoption and wind-power expansion, with supply expected to lag by up to 30%. The global REE market, valued at $3.95 billion in 2024, is forecast to reach $6.3 billion by 2030 at a compound annual growth rate of approximately 8.6%, according to Grand View Research.

China currently controls approximately 60% of REE mining and about 90% of processing capacity, prompting North American governments to accelerate domestic development. In 2025, the U.S. Department of Energy announced $1 billion in critical-minerals funding opportunities, while Canada’s C$1.5 billion Critical Minerals Infrastructure Fund supports projects through 2030. Together, this policy support and structural supply deficit highlight Powermax’s positioning within a strategically essential market tied to the clean-energy transition.

Leadership Team

Paul Gorman, CEO & Director, is a resource-based corporate specialist with more than 25 years of experience in junior mining finance, public listings, and corporate development. He is the President and Managing Partner of Riverbank Capital Inc., where he has raised over $150 million for emerging issuers and helped revitalize the North American graphite industry through the founding of Mega Graphite Inc. Gorman has led multiple exploration programs and was instrumental in achieving high-grade lithium discoveries in 2024 for Pan American Energy Corp.

Michael Malana, Director, has more than 20 years of international experience in financial management, reporting, and corporate governance. He has held senior executive roles across natural resources, biotechnology, and manufacturing and holds a Bachelor of Commerce degree from Concordia University in Montreal. Malana is a Chartered Professional Accountant (Certified Management Accountant).

Afzaal Pirzada, M.Sc., P.Geo., Director, is a professional geoscientist with over 30 years of experience in mineral exploration and mining, specializing in gold, lithium, graphite, rare metals, and uranium. He has served as Project Geologist, VP Exploration, Director, and CEO for multiple mining companies, including Adriana Resources and Rock Tech Lithium. Pirzada is a registered Professional Geoscientist with Engineers and Geoscientists British Columbia and has authored numerous NI 43-101 technical reports.

Powermax Minerals Inc. (OTCQB: PWMXF), closed Friday's trading session at $0.2465, up 7.1273%, on 40,101 volume. The average volume for the last 3 months is 93,300 and the stock's 52-week low/high is $0.22/$1.98.

Recent News

• Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) - MiningNewsBreaks - Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Positions Across Key North American Rare Earth Projects
• Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Atikokan Project Assay and Findings Identify Rare Earth Exploration Targets
• RockBreaks - Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Advances Amidst a New Critical Minerals Race

Earth Science Tech Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech Inc. (OTC: ETST).

Earth Science Tech (OTC: ETST) is positioned for opportunity as telehealth evolves from simple video visits into a comprehensive care model. “The company describes itself as a strategic holding company that acquires and actively manages operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and selected consumer markets. ETST’s healthcare-related holdings include telemedicine and pharmaceutical operations designed to support a more connected platform approach; in addition, its compounding operations through RxCompoundStore.com and Mister Meds directly align with the expanding digital healthcare segment,” reads a recent article. “Earth Science Tech recently reported that its operations include compounding pharmaceuticals, telemedicine, and real estate development… That portfolio matters because it suggests the company is not approaching telehealth as a standalone app or referral layer but as part of a broader operating structure that includes medication fulfillment capacity and patient-facing services.”

To view the full article, visit https://ibn.fm/aeGDz

Earth Science Tech Inc. (OTC: ETST) is a strategic holding company that builds value by acquiring and actively managing operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and select consumer markets. The company focuses on controlling interests in subsidiaries where operational oversight, regulatory compliance, and disciplined scaling can drive durable growth.

Since 2022, Earth Science Tech has completed a deliberate transition away from legacy activities and repositioned the organization around healthcare and pharmaceutical operations. That shift has been supported by regulatory alignment, expanding operating capabilities, and the assembly of a diversified portfolio of revenue-generating businesses.

Today, the company’s approach emphasizes execution, capital discipline, and long-term value creation across its operating platforms, with a focus on scaling businesses that can grow sustainably while enhancing shareholder value.

The company is headquartered in Miami, Florida.

Subsidiaries

Earth Science Tech conducts its operations through a portfolio of wholly owned and majority-owned subsidiaries spanning pharmaceutical compounding, telemedicine, healthcare services, real estate development, and direct-to-consumer products.

• RxCompoundStore.com LLC – A fully licensed compounding pharmacy based in Miami, Florida, authorized to fulfill prescriptions across more than 20 U.S. states and Puerto Rico, with ongoing licensure expansion efforts nationwide.
• Mister Meds LLC – A Texas-based compounding pharmacy operating from a 5,000-square-foot facility with advanced sterile and hazardous drug compounding capabilities, acquired to expand production capacity and geographic reach.
• Peaks Curative LLC – A telemedicine referral platform providing asynchronous consultations for Peaks-branded compounded medications, supported by an expanding provider network and recent entry into the veterinary market through Zoolzy.com.
• DOConsultations LLC – An online telehealth platform focused on customized medication formulations, supporting direct-to-patient delivery through partner pharmacies.
• Las Villas Health Care Inc. – A brick-and-mortar and telehealth healthcare provider serving the Spanish-speaking community, offering specialized wellness and sexual health services.
• Avenvi LLC – A diversified real estate development and asset management company overseeing property investments, development projects, and the company’s ongoing share repurchase program.
• MagneChef (80% interest) – A direct-to-consumer retail brand leveraging proprietary intellectual property to develop and market kitchen and cooking-related products, with recent expansion into premium American-made BBQ tools.
• Earth Science Foundation Inc. – A 501(c)(3) nonprofit organization serving as the company’s charitable arm, providing financial assistance for prescription costs to qualified individuals.

Collectively, these subsidiaries provide Earth Science Tech with diversified exposure across regulated healthcare services, digital health platforms, real estate assets, and proprietary consumer brands.

Market Opportunity

Earth Science Tech is primarily positioned within the pharmaceutical compounding and telemedicine markets, both of which are experiencing sustained growth driven by demand for personalized healthcare solutions, expanded access to care, and increasing adoption of remote service models.

The pharmaceutical compounding market continues to benefit from rising demand for customized medications, improved patient adherence, and supply-chain flexibility. According to Grand View Research, the global compounding pharmacies market was valued at approximately $13.1 billion in 2023 and is projected to reach $18.6 billion by 2030, representing a compound annual growth rate of 5.11% from 2024 to 2030. Earth Science Tech’s compounding operations through RxCompoundStore.com and Mister Meds align directly with this expanding market segment.

Telemedicine represents a second core growth vertical for the company, supporting the clinical delivery of pharmaceutical products and healthcare services. According to Fortune Business Insights, the global telemedicine market was valued at $111.99 billion in 2025 and is projected to grow to $532.08 billion by 2034, reflecting a compound annual growth rate of 20.0%, with North America accounting for approximately 48% of market share in 2025. Platforms operated by Peaks Curative and DOConsultations participate directly in this rapidly expanding digital health ecosystem.

Additional exposure to specialty healthcare clinics and real estate development provides diversification alongside the company’s core pharmaceutical and telemedicine operations.

Leadership Team

Giorgio R. Saumat, Chief Executive Officer and Chairman of the Board, is an investor and entrepreneur with more than 20 years of experience investing in, operating, and advising private businesses, including founding CASAU Group, a private equity firm focused on real estate, and POINT96 Consulting, which provides strategic planning services to businesses and accredited investors.

Ernesto L. Flores, Chief Financial Officer, is a financial executive with over a decade of experience in accounting, taxation, and financial management, having held senior roles overseeing compliance and financial operations at logistics and investment firms.

Mario G. Tabraue, President and Chief Operating Officer, brings experience across real estate, maritime operations, and digital infrastructure and was instrumental in acquiring RxCompoundStore.com with the vision of scaling it into a nationally competitive pharmaceutical and telemedicine platform.

Christopher Rose, Chief Technology Officer, is a technology and automation executive who previously led enterprise-wide automation initiatives at a Fortune 100 company, delivering large-scale operational efficiencies and global process automation.

Earth Science Tech Inc. (OTC: ETST), closed Friday's trading session at $0.145, up 3.5714%, on 110,200 volume. The average volume for the last 3 months is 139,750 and the stock's 52-week low/high is $0.001/$0.237.

Recent News

• Earth Science Tech Inc. (OTC: ETST) - BioMedNewsBreaks - Earth Science Tech Inc. (ETST) Aligns with Next Phase of Telehealth Through Integrated Platform
• NetworkNewsBreaks - Earth Science Tech Inc. (ETST) Advancing Multi-Platform Healthcare Strategy
• Earth Science Tech Inc. (ETST) Builds Integrated Healthcare Platform for Scalable Growth

American Fusion Inc. (OTC: AMFN)

The QualityStocks Daily Newsletter would like to spotlight American Fusion Inc. (OTC: AMFN).

American Fusion (OTC: AMFN) was featured in an AINewsWire editorial titled “Energy Constraints Emerging as Critical Factor in Sustaining AI Expansion,” highlighting the growing energy demands driven by increasingly complex artificial intelligence systems. The piece underscores how rising electricity consumption from data centers is straining infrastructure and emerging as a key limiting factor in AI growth, while positioning American Fusion at the intersection of advanced energy development and next-generation infrastructure through its focus on aneutronic fusion and scalable energy solutions designed to support AI-driven workloads.

To view the full press release, visit: https://ibn.fm/skPb7

American Fusion Inc. (OTC: AMFN) is an advanced energy platform company focused on building a scalable, infrastructure-grade fusion energy business through its wholly owned subsidiary, Kepler Fusion Technologies. Following a completed reverse merger with Kepler, the company has repositioned itself around the development and long-term commercialization of deployable fusion power systems designed for real-world industrial and infrastructure use rather than experimental research programs.

The company’s strategy centers on pairing proprietary fusion technology with disciplined governance, intellectual property development, and a public-company operating framework intended to support long-duration value creation. Management has emphasized transparency, regulatory readiness, and institutional credibility as foundational elements alongside continued technical progress.

The company is based in Southlake, Texas.

Kepler Texatron™

Through wholly owned subsidiary, Kepler Fusion Technologies, the company is developing the Texatron™ aneutronic fusion platform, a compact, pulsed fusion system engineered specifically for commercial and infrastructure-grade deployment. Unlike steady-state fusion concepts that prioritize laboratory demonstration, the Texatron™ operates in controlled cycles designed to support modular scalability, redundancy, and distributed installation across multiple end markets.

The platform is optimized around a Deuterium–Helium-3 fuel pathway that enables direct electrical energy conversion, reducing reliance on traditional steam cycles and minimizing neutron-related material degradation. This design supports a smaller physical footprint and greater flexibility for deployment in grid-constrained or mission-critical environments such as data centers, industrial facilities, defense installations, and remote locations.

Kepler’s commercialization model is structured around a Power-as-a-Service approach under which the company intends to retain ownership of its fusion units and sell electricity to customers under long-term contractual arrangements. This infrastructure-oriented model is designed to align system deployment with predictable, recurring revenue while allowing for fleet-based scaling over time. The platform is supported by a broad and expanding intellectual property estate encompassing reactor architecture, energy conversion systems, control technologies, manufacturing processes, and deployment methodologies.

Market Opportunity

U.S. electricity demand has re-entered a period of sustained growth following nearly two decades of relative stagnation, according to data from the U.S. Energy Information Administration. After years in which efficiency gains and structural economic shifts largely offset population and economic growth, electricity consumption has increased meaningfully since 2020 and is forecast to continue rising through at least the middle of the decade.

Recent and projected growth is being driven primarily by the commercial and industrial sectors, with data centers, advanced manufacturing, and other power-intensive operations accounting for a disproportionate share of incremental demand. These segments tend to require continuous, non-intermittent electricity supply, placing increased pressure on existing generation and transmission infrastructure.

This shift underscores a growing need for reliable baseload power sources that can be deployed without extensive new transmission build-out and that align with emissions-reduction objectives. Fusion-based energy systems designed for distributed, infrastructure-grade deployment represent a potential long-term solution for meeting rising demand in environments where reliability, resilience, and scalability are critical.

Leadership Team

Richard Hawkins, Chairman and Chief Executive Officer, has overseen the company’s strategic reset, corporate restructuring, and transition toward an advanced fusion energy platform, with responsibility for governance, capital markets strategy, and long-term corporate development.

Brent Nelson, Chief Executive Officer of Kepler Fusion Technologies, brings extensive experience in energy systems and commercialization strategy and leads the development, validation, and deployment roadmap for the Texatron™ fusion platform, as well as Kepler’s intellectual property and operating model.

American Fusion Inc. (OTC: AMFN), closed Friday's trading session at $0.0655, up 12.931%, on 9,338,152 volume. The average volume for the last 3 months is 8,248,720 and the stock's 52-week low/high is $0.000001/$0.08.

Recent News

• American Fusion Inc. (OTC: AMFN) - InvestorNewsBreaks - American Fusion Inc. (OTC: AMFN) Featured in AINewsWire Editorial on AI Energy Constraints
• AINewsBreaks - American Fusion Inc. (OTC: AMFN)?Positioned At Center Of AI-Driven Energy Demand Surge Alongside Major Industry Players
• AINewsBreaks - American Fusion Inc. (OTC: AMFN)?Featured in AINewsWire Editorial on AI-Driven Energy Demand

Oncotelic Therapeutics Inc. (OTCQB: OTLC)

The QualityStocks Daily Newsletter would like to spotlight Oncotelic Therapeutics Inc. (OTCQB: OTLC).

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech,” which highlights how late-stage drug development assets increasingly drive valuation in the biopharma sector. The editorial, supported by analysis from McKinsey & Company, notes that companies tend to realize the majority of value creation as products approach commercialization, reflecting reduced risk and clearer revenue visibility, a trend directly relevant to Oncotelic’s oncology-focused pipeline and strategic development approach.

To view the full press release, visit https://nnw.fm/42BlH

Oncotelic Therapeutics (OTCQB: OTLC) provided a corporate update emphasizing its partnership-driven strategy to advance its oncology and rare disease pipeline and enhance shareholder value. The company cited its joint venture with GMP Biotechnology, which contributed to a $249.0 million increase in its balance sheet based on an independent third-party valuation, and said it is pursuing additional collaborations to support development and commercialization efforts. Management noted the approach is designed to advance multiple drug candidates in parallel while maintaining capital efficiency and unlocking the value of its intellectual property portfolio.

To view the full press release, visit https://ibn.fm/Rv7Gc

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy, and targeted therapeutics for cancer and other underserved diseases. The company is focused on transforming outcomes for patients with difficult-to-treat and rare conditions, particularly pediatric cancers and aggressive solid tumors. Its development strategy centers on novel compound design, nanoparticle drug delivery, and the integration of artificial intelligence to accelerate discovery and regulatory workflows.

At the center of this foundation is Chairman and CEO Dr. Vuong Trieu, a prolific industry pioneer who has filed more than 500 patents with 75 issued patents across biologics, small molecules, nanoparticles, and diagnostics. Dr. Trieu co-invented Abraxane® (sold to Celgene for $2.9 billion), underscoring his track record of creating high-value therapies. Through collaborations with industry leaders and its stake in specialized joint ventures, Oncotelic is positioned to advance a diverse portfolio of oncology assets with greater speed and cost efficiency. The company also operates a proprietary AI platform, PDAOAI, which streamlines scientific writing, regulatory documentation, and data interpretation. This system is accessible to the public through a dedicated Discord server, offering real-time engagement with Oncotelic’s research ecosystem.

With expanded clinical activity and a next-generation development model, Oncotelic continues to evolve as a multi-asset innovator in precision oncology.

The company is headquartered in Agoura Hills, California.

Pipeline and Partnerships

Oncotelic’s lead candidate is OT-101, currently in a Phase 3 trial for pancreatic ductal adenocarcinoma (STOP-PC study) and evaluated in gliomas and metastatic solid tumors in combination with IL-2 and checkpoint inhibitors. The antisense molecule targets TGF-β2, a cytokine known to suppress immune responses and promote tumor growth. A Phase 1 trial combining OT-101 with IL-2 was recently completed, demonstrating safety and paving the way for combination therapies with PD-1 blockers and other immunotherapies.

Recent data have further strengthened the rationale for OT-101 in pancreatic ductal adenocarcinoma (PDAC). In June and July 2025, two peer-reviewed studies published in the International Journal of Molecular Sciences identified TGF-β2 gene expression and methylation status as significant prognostic markers in PDAC, particularly among younger patients and those with low CD8+ T-cell infiltration. High TGF-β2 expression correlated with reduced overall survival, while elevated TGF-β2 methylation was associated with improved outcomes. These findings validate TGF-β2 as a high-priority target and support the continued development of OT-101 as a precision therapy. Both studies leveraged Oncotelic’s proprietary AI-driven platform, PDAOAI, to mine and assemble multi-omic datasets, showcasing the system’s role in accelerating insight generation.

The company holds a 45% ownership stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited. GMP Bio owns SAPU Bioscience, which is executing several pipeline programs. SAPU and Oncotelic are jointly utilizing a rapid IND platform through their partnership with Shanghai Medicilon to support regulatory filings for up to 20 drug candidates, with five INDs already underway. This collaboration is central to accelerating development of next-generation anticancer agents.

After the joint venture, Dr. Trieu, with his team, built out a state of the art and GMP-certified R&D facility in San Diego, which operates under SAPU, that manufactures clinical trial materials and supports a proprietary nanoparticle platform trademarked Deciparticle ™. This platform includes four therapeutic candidates—two of which are in late-stage manufacturing and expected to enter IND filing before the end of 2025.

Additionally, Oncotelic owns AL-101, an intranasal administered apomorphine product intended for the treatment of Parkinson’s disease, Erectile Dysfunction, and Female Sexual Disorders.

Market Opportunity

Oncotelic is targeting large and underserved therapeutic markets with significant commercial potentials. The global pancreatic cancer treatment market alone is projected to grow at a 12.3% CAGR, reaching $5.84 billion by 2030, up from $2.92 billion in 2024, according to Research and Markets. This growth is driven by increased disease prevalence, aging populations, and demand for more effective treatment options. Notably, the incidence of early-onset PDAC is rising at an estimated rate of 4% per year in the 15–34 age group, highlighting an emerging unmet need for targeted therapies among younger patients.

Beyond oncology, Oncotelic intends to develop AL-101 for Parkinson’s disease, which affects over 1 million patients in the U.S. alone and is expected to impact 1.2 million by 2030. Erectile Dysfunction and Female Sexual Dysfunction are also major global health issues, with Erectile Dysfunction affecting up to 70% of men over 60 and Female Sexual Dysfunction impacting approximately 40% of women—both with limited treatment options, particularly for patients who fail to respond to existing medications. These underserved populations offer fertile ground for innovative new therapies.

Leadership Team

Dr. Vuong Trieu is the Chairman and CEO of Oncotelic Inc. An accomplished innovator in pharmaceutical development, Dr. Trieu previously served as President and CEO of Igdrasol, where he pioneered the approval path for paclitaxel nanomedicine via a single bioequivalence trial. After Igdrasol merged with Sorrento Therapeutics, he became Chief Scientific Officer and a Board Director. He also held leadership roles at Cenomed, Abraxis, Applied Molecular Evolution, and Parker Hughes Institute. Dr. Trieu holds a Ph.D. in Molecular Microbiology, a B.S. in Botany, has published widely, and filed over 500 patent applications with 75 issued U.S. patents.

Amit Shah is the Chief Financial Officer of Oncotelic Inc. He has over 20 years of financial leadership in life sciences, including CFO roles at Marina Biotech and Igdrasol, and senior positions at ISTA Pharmaceuticals, Spectrum Pharmaceuticals, and Caraco. He also worked in consulting and ERP implementation. Mr. Shah holds a Bachelor of Commerce from the University of Mumbai, is an Associate Chartered Accountant in India, and is an inactive CPA in Colorado.

Dr. Anthony E. Maida III is the Chief Clinical Officer – Translational Medicine at Oncotelic Inc. He has over 25 years of experience advancing cancer immunotherapies and held senior roles at Northwest Biotherapeutics, PharmaNet, and Jenner Biotherapies. He has raised over $200 million for biotech firms and negotiated licensing deals with institutions such as Pfizer, Eli Lilly, and Yale. Dr. Maida holds dual B.A. degrees in Biology and History, an MBA, an M.A. in Toxicology, and a Ph.D. in Immunology, and is active in ASCO, AACR, and other scientific societies.

Oncotelic Therapeutics Inc. (OTCQB: OTLC), closed Friday's trading session at $0.0378, up 3.3832%, on 342,935 volume. The average volume for the last 3 months is 259,560 and the stock's 52-week low/high is $0.015/$0.11.

Recent News

• Oncotelic Therapeutics Inc. (OTCQB: OTLC) - BioMedNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Partnership Strategy to Advance Pipeline
• NetworkNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on Pipeline-Driven Valuation
• BioMedNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In BioMedWire Editorial On Biotech Valuation Shift

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings (OTCQB: NGTF) announced the launch of a live pilot deployment of its autonomous robots, BIM-E and TIM-E, at the IOA Championship presented by Morongo Casino Resort and Spa, taking place April 24–26, 2026, at Morongo Golf Club at Tukwet Canyon in California. The deployment marks a key step in the company’s commercialization strategy, with the robots providing beverage service, waste management and delivery in a high-traffic event setting, while demonstrating scalability across outdoor hospitality environments. Following the event, the systems are expected to remain onsite for ongoing clubhouse operations, supporting continued validation as Nightfood advances production and scaling efforts in collaboration with Foxconn and NUWA Robotics.

To view the full press release, visit https://ibn.fm/U9tPA

Nightfood Holdings Inc. (OTCQB: NGTF) is a hospitality technology and asset acquisition company revolutionizing hotel operations through AI-driven service robotics and strategic property acquisitions. By integrating advanced automation solutions with high-value hospitality assets, NGTF is setting a new standard for operational efficiency, cost reduction, and labor optimization in the hospitality industry.

With a focus on Robotics-as-a-Service (RaaS) and hotel ownership, NGTF is uniquely positioned at the intersection of technology and real estate, creating scalable, revenue-generating solutions that drive the widespread adoption of automation in the hospitality sector.

Operations

Nightfood Holdings is focused on two core business areas:

• Hotel Acquisitions & Operations – NGTF is acquiring a portfolio of independent hospitality properties, spanning various market segments from midscale to luxury. These hotels serve as real-world testbeds for automation technologies, allowing NGTF to refine its RaaS solutions before deploying them at scale.
• Robotics-as-a-Service (RaaS) for Hospitality – NGTF provides subscription-based, AI-driven robotic automation, designed to optimize hotel operations. By deploying standardized automation solutions, NGTF helps hotels reduce costs, improve labor efficiency, and enhance guest experiences.

Through this fully integrated model, NGTF ensures that its robotics solutions are tested, optimized, and proven profitable before expanding to third-party hotel operators.

Market Opportunity

The demand for automation in hospitality is accelerating, driven by labor shortages, rising costs, and increased competition. NGTF is positioned to capitalize on this shift through its combined hotel ownership and RaaS strategy.

• Total Addressable Market (TAM): The global service robotics market is projected to reach approximately $107.75 billion by 2030, driven by widespread adoption across industries including hospitality, according to Research and Markets.
• Serviceable Available Market (SAM): The global smart hospitality market, which includes AI and automation technologies for hotels, is projected to reach $186.10 billion by 2032, according to SNS Insider.
• Competitive Positioning: NGTF’s unique real estate + automation model allows it to implement cost-saving robotics solutions in real-world environments before expanding adoption across the industry.

Industry Impact: The Future of Smart Hotels

NGTF is at the forefront of next-generation hospitality automation, transforming how hotels operate. By combining AI-powered service robotics with real estate acquisitions, NGTF is pioneering the transition to smart, highly efficient hotel environments.

Hotels acquired by NGTF serve as testing grounds for robotics deployment, allowing the company to continuously refine its automation solutions. The biggest industry benefits include:

• Cost Savings for Hotel Operators – Reducing labor costs and improving operational efficiency.
• Scalability & Standardization – Offering a streamlined, subscription-based RaaS model for seamless automation adoption.
• Industry Leadership in Hotel Robotics – Driving the transformation of hospitality with AI-powered automation solutions.

Future Vision & Growth Strategy

Over the next three to five years, NGTF is committed to scaling both its hotel portfolio and RaaS adoption. By refining and optimizing its automation technologies in its own properties, NGTF will continue deploying RaaS to third-party hotel operators, positioning itself as a leader in next-generation hospitality automation.

Through strategic acquisitions and AI-driven solutions, NGTF is defining the future of smart hotels—delivering cost-efficient, scalable automation that reshapes the hospitality landscape.

Team Expertise as a Strategic Advantage

In addition to technology and real estate, NGTF’s most powerful asset is its team. The company’s leadership and operating partners bring deep expertise in both hospitality and food service, having collectively developed over 50 properties, managed more than 130 hotels, and supported more than 6,000 quick-service restaurants.

This wealth of experience enables NGTF to execute its automation and acquisition strategy with operational discipline, industry insight, and scale—further strengthening its position in next-generation hospitality.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Friday's trading session at $0.029591, up 5.6821%, on 1,018,207 volume. The average volume for the last 3 months is 1,372,080 and the stock's 52-week low/high is $0.0112/$0.114.

Recent News

• Nightfood Holdings Inc. (OTCQB: NGTF) - TechMediaBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Launches Live Robot Pilot at IOA Championship
• TechMediaBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Highlights Growth Momentum and Expansion Plans in Service Robotics
• AINewsBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Advances Commercialization With Robotics Supply Agreement

Astiva Health

The QualityStocks Daily Newsletter would like to spotlight Astiva Health

Last fall, Johns Hopkins School of Nursing through its Institute for Policy Solutions conducted a survey on health inequities and the full report from that survey was released weeks ago. The findings of that poll offer valuable insights that policymakers and all stakeholders need to weigh while making decisions impacting the health of Americans. The majority (70%) of the respondents say health care is a right and that it shouldn’t be treated as a privilege. The survey found that while there is a sense that Americans are heavily polarized on national issues, this isn’t the case when it comes to matters of health care. Notably, 62% of those who participated in the survey revealed that improving health care for everyone will be extremely important or very important as they make voting decisions during the upcoming midterms. This suggests that candidates who are passionate about removing inequities on matters of health care could have an upper hand in appealing to voters. Guilamo-Ramos, the ED of the Institute for Policy Solutions, says there is a need to shift from thinking that steps taken to improve health care for a certain group means that something has to be taken from another group. He explains that the best way to address these issues is by setting universal targets and then directing more effort to fix the systemic issues impacting the most vulnerable groups so that they can be brought to the same level as others who don’t face the same hurdles. For firms like Astiva Health that focus on providing health coverage to vulnerable communities like racial minorities, the realities of the inequities in health care access and delivery are all too apparent and addressing those issues in a systemic way would be hugely welcomed. 

Astiva Health is a dynamic and innovative Medicare Advantage Prescription Drug (MAPD) health plan committed to reshaping the landscape of personalized and comprehensive healthcare. The company offers full medical, drugs, and supplemental benefits for Medicare enrollees, currently serving counties in California, including Orange, San Diego, Los Angeles, Riverside, and San Bernardino. This broad coverage reflects Astiva Health’s dedication to reaching a diverse demographic and addressing the healthcare needs of individuals across Southern California.

Astiva Health primarily serves a heretofore underserved Asian American and Pacific Islander population, which positions it in a critical and expanding market segment and offers substantial growth potential. The company recognizes the diverse needs within its served communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions.

Astiva Health cares about its members and works to establish lifelong relationships with them by providing a tailored approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Health is an essential key to living a good life, and Astiva Health makes it a priority to help members love the life they live.

The company’s mission is to deliver an unparalleled level of quality care to its members. Astiva Health’s Medicare Advantage plans provide lower costs and additional benefits beyond original Medicare coverage.

Founded in southern California, Astiva Health has strategically positioned itself in a region with a dynamic and diverse population. The organization’s extensive network and culturally responsive approach to healthcare make it well-suited to cater to the needs of the local community, creating a competitive advantage in the market.

The company is based in Orange, California.

Healthcare Model

Astiva Health is not just another health plan. The company considers the uniqueness of its members and, therefore, the means for delivering quality care to each one. To best serve its members, Astiva Health has developed one of the most diverse networks in southern California, offering a selection of medical, drugs, and supplemental benefits including dental, acupuncture, vision and hearing plans tailored to the specialized needs of individual members.

The company’s health plans provide increasing levels of benefits to members in the counties it serves. Astiva Health’s Customer Care Support and representatives are available to assist members with any issues.

The organization’s proactive approach to overcoming language barriers for the Vietnamese communities demonstrates a commitment to inclusivity and enhances accessibility – a key factor for future growth. The successful implementation of strategies for the Vietnamese community sets a precedent for Astiva Health’s ability to adapt and apply similar approaches to serve other ethnic groups in future expansions, broadening the potential impact of its services.

The company provides members access to experienced and dedicated providers and local pharmacies that work together with each member to pave a pathway toward better health. The company’s online directory provides members with a comprehensive list of providers to fit their specialized needs.

Astiva Health collaborates with a variety of partners who offer supplemental benefits to members beyond Medicare. Those benefits include transportation, vision, dental, hearing, fitness, tele-health, acupuncture and chiropractic. Astiva’s forward-thinking strategy not only fulfills a critical societal need but also ensures sustainable growth and transformative impact across diverse communities.

Market Opportunity

Medicare Advantage plans, since their establishment in 2008 as a lower-cost alternative for Medicare enrollees looking to save on monthly premiums, have been one of the fastest growing segments of the health insurance market.

According to a report by healthcare consultant Charts, nearly 31 million beneficiaries are enrolled in a Medicare Advantage plan in 2023, accounting for more than 48% of the total Medicare market. That represents 9.6% enrollment growth over 2022 totals, and the pace of growth is likely to continue, according to the Charts report.
Startup Medicare Advantage plans, a sector that includes Astiva Health, grew even faster for 2023, at a rate of 22% over 2022 totals.

Management Team

Dr. Tri T. Nguyen is co-founder and CEO of Astiva Health. He is a graduate of Stanford Medical School and is a board-certified expert in internal medicine, cardiovascular disease and interventional cardiology. As founder, CEO and owner/operator of Avanta IPA, he is a committed leader in healthcare. His visionary leadership, hands-on experience and deep industry knowledge uniquely position him to guide Astiva to success.

Chi Luong is CFO at Astiva Health. She founded and operates HADD Group LLC, a company managing medical clinic services, including business contracting, finance, staffing and ancillary support for several medical clinics in San Diego. She is responsible for the expansion and daily operation of the business functions of the medical clinics managed by HADD Group, and she has extensive knowledge and experience in healthcare business development.

Viet Tran has over 30 years of experience in engineering research, development and management. He has made numerous contributions to national network security and technology. He led the initial Naval Interoperability Profiles that set a solid foundation for future naval airborne network development. He also led a team of 50 engineers, doctorates and scientists delivering an airborne network system for the Navy’s first carrier-based unmanned aircraft. As Astiva Health’s Chief Operating and Technology Officer, member satisfaction has been his top priority. He is committed to protecting valuable data for Astiva members and providers. He constantly strives for leaner and more effective operations.

Tyler Diep is Vice President, Sales, Marketing and Provider Relations at Astiva Health. His responsibilities include handling special projects for the board of directors, as well as overseeing the sales, marketing and provider relations department. During his tenure, he tripled the membership of Astiva Health. He previously served as councilman and vice mayor of the City of Westminster, California. He immigrated to the U.S. with his parents and graduated from San Diego State with a bachelor’s degree in public administration.

Recent News

• Astiva Health - Survey Finds That American Adults Want Health Inequities Eliminated
• Shares of Health Insurers Rally After CMS Bumps Up 2027 Rates
• Gallup Poll: Healthcare Returns to the Top of Americans’ Biggest Domestic Worries

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO)

The QualityStocks Daily Newsletter would like to spotlight Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO).

• At the core of Cardio Diagnostics’ approach is the use of artificial intelligence to integrate multi-omic data to provide a more comprehensive view of cardiovascular health.
• The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk.
• CDIO’s focus on accessibility and scalability is also notable.

Cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. Cardio Diagnostics Holdings (NASDAQ: CDIO) is at the forefront of this shift, developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk assessments from a simple blood sample.

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators.

At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more complete view of cardiovascular disease.

Cardio Diagnostics was founded to develop and commercialize clinical tests and data solutions that enable earlier detection and more precise management of cardiovascular disease across clinical and non-clinical settings.

The company is headquartered in Chicago, Illinois.

Portfolio

The company’s portfolio brings together epigenetic and genetic insights with artificial intelligence to generate actionable information for cardiovascular care. This approach underpins a suite of blood-based tests and platforms designed for use across both individual patient care and broader population health settings.

Epi+Gen CHD™

Epi+Gen CHD™ is a prescription-only blood test that assesses a patient’s three-year risk of a coronary heart disease (CHD) event, including heart attack and sudden death. The test evaluates three epigenetic and five genetic biomarkers and applies artificial intelligence to generate a personalized risk score. It is designed to assess risk regardless of the presence of traditional factors and is non-invasive, requiring no fasting or radiation. In clinical validation studies, the test has demonstrated approximately two times greater sensitivity than conventional risk calculators and enables ongoing monitoring through epigenetic biomarkers that can change in response to intervention.

PrecisionCHD™

PrecisionCHD™ is a prescription-only blood test that aids in the detection and management of coronary heart disease by identifying molecular signals associated with the condition. The test evaluates 10 epigenetic and six genetic biomarkers and uses artificial intelligence to determine whether a disease signal is present. It provides patient-specific insights into the molecular drivers of disease, supporting more individualized care decisions, and is designed to detect both obstructive and non-obstructive forms of CHD in a non-invasive manner.

HeartRisk™

HeartRisk™ is a population-level cardiovascular risk intelligence platform that integrates anonymized clinical, claims, industry, and geographic data to provide real-time insights into heart disease risk across defined populations. The platform enables organizations to quantify risk, project future healthcare costs, benchmark against peer groups, and track changes over time, supporting more informed planning and risk management strategies.

CardioInnovate360™

CardioInnovate360™ is a biopharma research platform that leverages artificial intelligence and epigenetics to support the discovery, development, and validation of cardiovascular therapies. The platform is designed to identify novel biomarkers and disease pathways, optimize clinical trial design through improved patient stratification, and enable the development of scalable, non-invasive diagnostic tools.

Market Opportunity

Cardiovascular disease (CVD) is the leading cause of death in the United States, responsible for nearly one in three deaths. It encompasses a range of conditions, including CHD, stroke, heart failure, and peripheral artery disease, and continues to represent a significant and persistent healthcare burden.

Coronary heart disease is the most common form of CVD and often develops without symptoms, with a heart attack frequently serving as the first indication of disease. In the U.S., one in 20 adults over the age of 20 lives with CHD, and it is the second leading cause of hospitalization, adding approximately $13,000 in annual healthcare costs per patient. An additional three to four million Americans are affected by ischemia with no obstructive coronary arteries (INOCA), a subset of CHD.

Heart attacks occur approximately every 40 seconds in the U.S., with more than 800,000 events annually, and one in five occurring without warning. While an estimated 80–90% of cardiovascular disease is preventable through early detection and proactive management, traditional approaches can leave gaps, as approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%.

Leadership Team

Meesha Dogan, PhD, Chief Executive Officer and Co-Founder, has served as CEO and a director since inception and co-founded the company alongside Dr. Philibert. She has more than a decade of experience working at the intersection of artificial intelligence, epigenetics, and genetics, leading the development and commercialization of DNA-based cardiovascular tests. Dr. Dogan is an inventor on multiple granted and pending patents and holds a PhD in Biomedical Engineering and BSE/MS degrees in Chemical Engineering from the University of Iowa.

Robert Philibert, MD, PhD, Chief Medical Officer and Co-Founder, has served as CMO and a director since inception and co-founded the company with Dr. Dogan. He is a professor at the University of Iowa with joint appointments across psychiatry, neuroscience, molecular medicine, and biomedical engineering, and has published more than 200 peer-reviewed manuscripts. Dr. Philibert has received numerous NIH grants and holds patents related to epigenetics, including work on behavioral biomarkers.

Tim Dogan, PhD, Chief Technology Officer, has served as CTO since May 2022 after joining the company in 2019 as its first employee. He played a key role in developing the company’s Integrated Multi-Omics Engine™ and is a co-inventor on multiple patent-pending technologies. Dr. Dogan holds a PhD and BSE/MS degrees in Mechanical Engineering from the University of Iowa.

Elisa Luqman, JD, MBA, Chief Financial Officer, has served as CFO since March 2021 and has experience in public company finance, compliance, and corporate governance. She has held senior leadership roles at Clinigence Holdings Inc. and currently serves as Chief Legal Officer (SEC) at Nutex Health Inc., overseeing SEC reporting and compliance. Ms. Luqman holds a JD and MBA in Finance from Hofstra University.

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO), closed Friday's trading session at $1.82, even for the day, on 30,670 volume. The average volume for the last 3 months is 143,438 and the stock's 52-week low/high is $0.97/$15.

Recent News

• Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) - Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) AI Platform Brings Precision to Heart Health
• InvestorNewsBreaks - Why Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is 'One to Watch'
• BioMedNewsBreaks - Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Engages IBN to Support Corporate Communications Strategy

Strawberry Fields REIT Inc. (NYSE American: STRW)

The QualityStocks Daily Newsletter would like to spotlight Strawberry Fields REIT Inc. (NYSE American: STRW).

Strawberry Fields REIT (NYSE AMERICAN: STRW) announced it will report its first quarter 2026 financial results before the market opens on May 8, 2026, and will host a conference call and webcast at 12:00 p.m. Eastern Time the same day to discuss the results. Investors are invited to pre-register for the call to receive dial-in details, while a live listen-only webcast and a replay will be available via the company’s website.

To view the full press release, visit https://ibn.fm/whpPm

Strawberry Fields REIT Inc. (NYSE American: STRW) is a self-administered real estate investment trust engaged in the ownership, acquisition, development, and leasing of skilled nursing and other healthcare-related properties. Initially spun out in 2015 with a 33-property portfolio in Indiana and Illinois, the company has steadily expanded its footprint and now owns and leases across 10 states. Its facilities are leased to experienced third-party operators, primarily under long-term triple-net agreements.

The company’s disciplined strategy emphasizes working with regional operators and experienced consultants, focusing on markets where demographic tailwinds and regulatory barriers support long-term demand. From 2020 through projected 2025, the company achieved compound annual growth rates of 13.6% in Adjusted Funds From Operations (AFFO) and 13.5% in Adjusted EBITDA (AEBITDA).

In August 2025, the board of directors approved a 14.3% increase in the company’s quarterly dividend to $0.16 per share. Chairman and CEO Moishe Gubin stated that the dividend increase reflects the company’s strong performance and sustainable outlook, while still keeping the payout ratio below 50%.

Strawberry Fields REIT is headquartered in South Bend, Indiana.

Portfolio

As of September 2025, Strawberry Fields REIT owns and holds long-term leasehold interests in 142 healthcare facilities totaling more than 15,500 licensed beds. The portfolio includes 130 skilled nursing facilities (SNFs), 10 assisted living facilities (ALFs), and two long-term acute care hospitals (LTACHs), with properties located in Arkansas, Illinois, Indiana, Kansas, Kentucky, Missouri, Ohio, Oklahoma, Tennessee, and Texas.

In recent months, Strawberry Fields REIT has expanded its portfolio through the following acquisitions:

• Nine skilled nursing facilities in Missouri totaling 686 beds for $59 million. Eight of the facilities were added to an existing master lease with the Tide Group, increasing annual base rent by $5.5 million, while the ninth facility was added to Reliant Care Group’s lease, raising rent by an additional $0.6 million.
• An 80-bed skilled nursing facility near Oklahoma City, Oklahoma, for $4.25 million, which was leased to a current operator under a master lease with $425,000 of initial rents and 3% annual escalations.
• A 124-bed facility comprised of 108 skilled nursing beds and 16 assisted living beds near Poplar Bluff, Missouri, for $5.3 million, which was leased to a current operator under a master lease with $530,000of initial rents and 3% annual escalations.

Market Opportunity

Strawberry Fields REIT operates in the skilled nursing and post-acute healthcare real estate sector, which is supported by favorable demographic and regulatory trends. The U.S. population aged 65 and older is expected to exceed 72 million by 2030 and reach 88.5 million by 2050. According to the CDC, 83.5% of skilled nursing facility residents are 65 or older.

The sector benefits from high barriers to entry, including regulatory constraints, capital requirements, and operational complexity. At the same time, government programs such as Medicare and Medicaid provide a stable reimbursement base. The company noted that despite challenges, its operators have demonstrated consistent profitability in states that are traditionally considered difficult for SNF operators.

Spending on SNF care for the aging population is projected to grow from $181.6 billion in 2021 to $273 billion in 2030, reflecting a compound annual growth rate of 4.63%. Strawberry Fields REIT’s geographic clustering strategy and long-term lease structure position it to benefit from this increasing demand and constrained supply.

Leadership Team

Moishe Gubin, Chairman, CEO, and Founder, has served as CEO since the company’s inception and was involved in every acquisition. He previously served as CFO and manager of Infinity Healthcare Management and is a licensed CPA in New York.

Jeffrey Bajtner, Chief Investment Officer and Chief Operating Officer, joined the company in 2021. He oversees acquisitions, dispositions, and investor relations. Previously, he held leadership roles at BlitzLake Partners and NorthStar Realty Finance. He is a licensed CPA in Illinois.

Greg Flamion, Chief Financial Officer, joined in January 2024. He was formerly CFO at Zimmerman Advertising and has held senior finance roles at Diageo and Bristol Myers Squibb. He holds an MBA from the University of Florida and is a CPA licensed in Indiana.

Steven Greenfield, General Counsel, joined in April 2025. He previously served as Managing Attorney at HammondLaw and held executive and legal positions at Weil, Gotshal & Manges LLP and Mayer Brown LLP, focusing on tax and securities law.

Strawberry Fields REIT Inc. (NYSE American: STRW), closed Friday's trading session at $12.37, off by 0.6425703%, on 13,723 volume. The average volume for the last 3 months is 25,684 and the stock's 52-week low/high is $9.4572/$14.

Recent News

• Strawberry Fields REIT Inc. (NYSE American: STRW) - MissionIRNewsBreaks - Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) Schedules Q1 2026 Earnings Release and Conference Call
• InvestorNewsBreaks - Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) Declares $0.16 Dividend, Sets Annual Meeting Date
• NetworkNewsBreaks - Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) Featured in NetworkNewsAudio Editorial on Healthcare REIT Momentum

Rail Vision Ltd. (NASDAQ: RVSN)

The QualityStocks Daily Newsletter would like to spotlight Rail Vision Ltd. (NASDAQ: RVSN).

Rail Vision (NASDAQ: RVSN) is poised for opportunity as the global train collision avoidance market is undergoing a dramatic transformation, driven by the convergence of advanced camera systems and artificial intelligence. The company is “developing proprietary AI-integrated sensing platforms designed to detect hazards in real time and ultimately enable fully autonomous train operations,” reads a recent article. “Israel-based Rail Vision has built its technology around the idea that the most dangerous moments for a train are the ones no one planned for. The company’s offerings have been described as AI-powered perception systems that allow rail operators to predict and prevent collisions, operating directly onboard locomotives rather than relying on wayside infrastructure or static signaling systems. This onboard approach is central to the company’s philosophy: that safety must travel with the train itself.”

To view the full article, visit https://ibn.fm/mDULk

Rail Vision Ltd. (NASDAQ: RVSN) is an early commercialization-stage technology company developing unique rail-specific detection systems designed to improve safety and operational performance across global railway networks. The company’s products address visibility, hazard detection, and situational awareness challenges, which are critical for preventing collisions, reducing operational risks, and improving overall railway efficiency in diverse and demanding environments.

Rail Vision’s technology combines electro-optical sensors with artificial intelligence to extend real-time awareness along and around rail tracks under a wide range of operating conditions. The company aims to support safer train movement, improve operational reliability, and enhance decision-making for both manned and increasingly automated rail systems.

Rail Vision aims to deliver measurable safety, efficiency, and cost benefits for passenger and freight operators, while contributing to the continued evolution of modern rail infrastructure.

The company is headquartered in Ra’anana, Israel.

Products

Rail Vision offers two primary rail-deployed systems, MainLine and ShuntingYard, designed for distinct operating environments, along with a cloud-based operational intelligence dashboard that extends system functionality through data analysis and reporting.

• The MainLine system provides extended forward-looking visibility of up to 1.2 miles along open rail corridors, enabling real-time detection and classification of obstacles, hazards, and track-related events across a wide range of weather and lighting conditions. Designed for continuous operation, the system delivers real-time alerts that enhance driver awareness, improve safety, and increase operational efficiency.
• The ShuntingYard system detects hazards and provides visibility of up to 200 yards under diverse weather and lighting conditions along rail yards. The system offers front-to-back visual coverage, wide-view coupling cameras, and path-finding capabilities to support safe maneuvering in dense, low-speed operational settings.

Both systems are complemented by visual and acoustic alerts intended to reduce collision risk, minimize operational downtime, and improve efficiency during complex operations.

Rail Vision also offers a cloud-based SaaS intelligence portal that aggregates and analyzes data generated by Rail Vision’s products. This platform is designed to empower operators with the tools they need to efficiently manage their fleets, review historical data, and generate comprehensive reports, ultimately reducing downtime, lowering costs, and integrating Rail Vision’s data outputs with existing or future big data environments.

Additional offerings include system software updates, parts and repairs, support services, and tailored integrations.

Market Opportunity

Rail Vision operates within a growing global market driven by increasing demand for railway safety, operational efficiency, and automation. According to Research and Markets, the train collision avoidance systems market was estimated at approximately $20.3 billion in 2024 and is projected to reach $57.8 billion by 2030, representing a compound annual growth rate of 19.0% over that period. This growth reflects heightened focus on accident prevention, infrastructure modernization, and regulatory emphasis on safety.

In parallel, the global autonomous train market was estimated at $9.82 billion in 2023 and is expected to reach $14.50 billion by 2030, growing at a CAGR of 5.9% from 2024 to 2030, according to Grand View Research. Market trends supporting these opportunities include expansion of global rail networks, rising adoption of artificial intelligence and cloud-based services in railway operations, and increased investment in research and innovation related to AI-enabled rail technologies. Together, these dynamics position Rail Vision within markets that are expanding in both scale and technological sophistication.

Leadership Team

David BenDavid, Chief Executive Officer, is a technology executive with more than 25 years of global experience driving innovation across artificial intelligence, cloud computing, and advanced engineering platforms. Prior to joining Rail Vision, he served as CEO and co-founder of Tensorleap, where he led the development of a deep learning analytics platform focused on transparency and performance in AI model deployment.

Ofer Naveh, Chief Financial Officer, brings more than 20 years of experience in accounting and financial management, including roles at KPMG’s audit practice and in senior finance positions at publicly traded companies in Israel and the United States. He holds a B.A. in Accounting and Business and an M.A. in Law.

Noam Shloper, Chief Operating Officer, has more than 20 years of experience in executive compliance, quality management, and project management across military and commercial high-technology environments. He previously served in senior quality and operations roles at DRS Rada Technologies and Logic Industries and holds a degree in Industrial and Management Engineering.

Doron Cohadier, Vice President of Business Development and Marketing, has over two decades of managerial experience in business development and marketing within advanced technology sectors. His background includes senior leadership roles at Foresight Autonomous Holdings and Elbit Systems, supporting global commercialization of vision and defense technologies.

Amit Klir, Vice President of Research and Development, has extensive experience leading multidisciplinary engineering teams and managing the development of products combining video processing, signal processing, and advanced algorithms. He holds a B.Sc. in Electrical and Computer Engineering with a specialization in digital signal processing.

Rail Vision Ltd. (NASDAQ: RVSN), closed Friday's trading session at $7.65, off by 6.6504%, on 19,248 volume. The average volume for the last 3 months is 17,414 and the stock's 52-week low/high is $3.66/$29.571.

Recent News

• Rail Vision Ltd. (NASDAQ: RVSN) - TinyGemsBreaks - Rail Vision Ltd. (NASDAQ: RVSN) Integrating AI and Imaging to Redefine Train Safety Systems
• AINewsBreaks - Rail Vision Ltd. (NASDAQ: RVSN) Deploys AI, Thermal Imaging to Redefine Rail Safety
• Safe Pro Group Inc. (NASDAQ: SPAI) Appoints Chief Operating Officer, Is Also Awarded Government Support Order for its Edge Processing Solution

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

The QualityStocks Daily Newsletter would like to spotlight LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT).

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is advancing the precision oncology landscape, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. “The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects,” reads a recent article. “By focusing on improving the therapeutic index of existing cancer modalities, the company is tackling a recurrent challenge in the field of oncology: maximizing treatment impact while cutting down risks to healthy tissue.”

To view the full article, visit https://ibn.fm/EE6ya

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is a clinical-stage pharmaceutical company developing differentiated cancer therapies built around a novel biological target. Rather than introducing standalone treatments, the company is focused on advancing a first-in-class approach designed to enhance the effectiveness of established cancer therapies, addressing persistent challenges that continue to limit outcomes in oncology.

LIXTE’s work centers on improving how chemotherapy and immunotherapy perform in difficult-to-treat cancers with significant unmet medical need. By translating a distinct scientific concept into therapies that can be integrated into existing treatment frameworks, the company aims to expand the reach and impact of current standards of care without requiring wholesale changes to clinical practice.

Alongside internal development, LIXTE has pursued selective strategic actions that extend its capabilities beyond drug development, supporting its evolution into a platform-oriented oncology company spanning both pharmaceutical and technology-driven approaches.

The company is headquartered in Boca Raton, Florida.

Portfolio

LB-100 (PP2A Inhibitor Platform)

LIXTE’s lead clinical candidate, LB-100, is a proprietary small-molecule inhibitor of protein phosphatase 2A (PP2A) designed to enhance the activity of chemotherapy and immunotherapy. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by more than 25 published preclinical and translational studies. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with limited treatment options.

Ongoing trials include combinations of LB-100 with immunotherapy in ovarian clear cell carcinoma and metastatic MSI-low colon cancer, as well as combination therapy with chemotherapy in advanced soft tissue sarcoma. These studies are being conducted in collaboration with leading academic cancer centers and industry partners, reflecting LIXTE’s emphasis on externally validated clinical execution.

Radiotherapy Platform Expansion (Liora Technologies)

In November 2025, LIXTE expanded beyond pharmaceuticals with the acquisition of Liora Technologies Europe Ltd., adding an electronically controlled proton therapy platform known as the LiGHT System. This acquisition established LIXTE’s entry into radiotherapy, complementing its drug development activities and creating optionality for future recurring revenue models tied to jointly operated treatment centers.

Market Opportunity

LIXTE is targeting cancers where existing therapies show limited durability due to resistance, toxicity constraints, or suboptimal patient response. Chemotherapy and immunotherapy are widely applicable across tumor types but remain constrained by these factors, creating an opportunity for approaches that improve efficacy without proportionally increasing toxicity.

The company’s clinical programs focus on ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma, indications characterized by high unmet need and limited effective treatment options. Rather than reshaping oncology care, LIXTE is developing LB-100 to augment existing therapies, an approach that could support wider clinical use within established treatment pathways.

Leadership Team

Geordan Pursglove, Chairman, President and Chief Executive Officer, is an accomplished executive and entrepreneur with more than a decade of experience spanning mergers and acquisitions, capital markets, strategic growth initiatives, and operational leadership across both public and private companies. His background includes leadership roles across technology, logistics, customer experience, sports, and marketing, with a focus on scaling organizations, raising capital, and executing transformative strategies.

Bas van der Baan, Chief Scientific Officer, has more than 20 years of experience in biotechnology with a concentration in oncology and diagnostics. He previously served as Chief Clinical and Business Development Officer at Agendia, where he played a key role in initiating and executing clinical trials that supported the commercialization of precision molecular oncology diagnostics in both the U.S. and Europe.

Peter Stazzone, Chief Financial Officer, brings over two decades of financial management experience across publicly traded and privately held companies. His background includes leading capital raises, mergers and acquisitions, financial controls, and public company reporting, with prior CFO roles at companies including Beyond Commerce, Strainz, and Voice Telecom.

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), closed Friday's trading session at $3.71, off by 6.7839%, on 52,014 volume. The average volume for the last 3 months is 46,041 and the stock's 52-week low/high is $0.64/$6.26.

Recent News

• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) - TinyGemsBreaks - LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment
• MissionIRNewsBreaks - LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape
• Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built